Application prospects of urine-derived stem cells in neurological and musculoskeletal diseases

doi:10.5312/wjo.v15.i10.918

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1224)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

HTML

752

Figures (1-2)

Tables (1-3)

132

Sum=975

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

101

Sum=168

Publishing Process of This Article

Item

Count

Browse

Download

Sum=52

Oct 18, 2024 (publication date) through Nov 24, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Orthopedics

ISSN

2218-5836

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Orthop. Oct 18, 2024; 15(10): 918-931
Published online Oct 18, 2024. doi: 10.5312/wjo.v15.i10.918

Table 1 Surface markers of urine-derived stem cells

Surface markers in USCs		Ref.
MSC-like markers	CD73, CD90, CD29, CD44, CD146
	CD73, CD29, CD44
	CD73, CD90, CD44, CD146
	CD73, CD90, CD105 (high), CD44, CD146
	CD73, CD90, CD146
	CD73, CD90, CD105, CD29, CD24, CD146
	CD73, CD90, CD29
	CD73, CD90, CD29, CD44, CD54, CD166, CD146
	CD73, CD90, CD105, CD29, CD44
	CD90, CD29, CD44
	CD73, CD90, CD105, CD29, CD44, CD166, STRO-1, CD54, CD146
	CD73, CD90, CD105, CD44
	CD73, CD90, CD105, STRO-1 (low), CD146
	CD73, CD90, CD105, CD24, CD29, CD44, CD117, STRO-1, CD146
	CD29, CD44, CD73, CD90, CD105 (low)
	CD24, CD29, CD34, CD44, CD73, CD90
Other pluripotency markers	TRA-1-60, TRA-1-81, SSEA-4, SOX2, OCT4, MYC, KLF4
	SSEA-4
	OCT4, MYC
	OCT4, NANOG	[20]
	CD133
Urinary system markers	Nephrin, WT1	[20]
	PAX2, PAX8
	Uroplakin Ia, cytokeratin 7, cytokeratin 19
MP markers	PAX7, MYF5, MOYD, desmin, dystrophin, myogenin, α-smooth muscle actin	[24]

CD: Cluster of differentiation; KLF: Kruppel-like factor 4; MP: Myogenic pedigree; MSC: Mesenchymal stem cells; MYC: Myelocytomatosis oncogene; MYF: Myogenic factor 5; NANOG: Nanog homeobox; OCT4: Octamer binding transcription factor 4; PAX: Paired-box; SOX2: Sex determining region Y-box 2; SSEA-4: Stage-specific embryonic antigen-4; STRO-1: Stromal cell antigen-1; TRA: Tumor resistance antigen; USCs: Urine-derived stem cells; WT: Wilms’ tumor.

Citation: Yang HS, Zheng YX, Bai X, He XY, Wang TH. Application prospects of urine-derived stem cells in neurological and musculoskeletal diseases. World J Orthop 2024; 15(10): 918-931
URL: https://www.wjgnet.com/2218-5836/full/v15/i10/918.htm
DOI: https://dx.doi.org/10.5312/wjo.v15.i10.918